Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Please provide your email address to receive an email when new articles are posted on . An updated guideline on the prevention and management of atrial fibrillation includes a new staging system to ...

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

City-based Kauvery Hospital launched advanced electroanatomical mapping technology on Thursday for the treatment of complex heart rhythm disorders, including atrial fibrillation and ventricular ...

The management of atrial fibrillation (AF) focuses on control of heart rate, correction of rhythm disturbance, prophylaxis of thromboembolism, treatment of underlying disorders, and pathophysiologic ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person’s risk of stroke, heart failure and even premature death. While many risk factors contribute to A-fib, one stands ...

Patients with newly diagnosed atrial fibrillation benefit from early rhythm control therapy, according to new results. Patients with newly diagnosed atrial fibrillation benefit from early rhythm ...

The management of patients with atrial fibrillation involves three main areas: anticoagulation, rate control and rhythm control. Importantly, these are not mutually exclusive of each other.

ST. LOUIS — Dr. Paban Saha, an Electrophysiologist with Prairie Cardiovascular, discusses atrial fibrillation. What is Atrial Fibrillation (A-fib)? A-fib is a common heart condition where the heart ...

The rhythm is either sinus rhythm or not sinus rhythm. Sinus rhythm refers to the origination of the electrical activity coming from the sinus node — also known as the sinoatrial node, or SA node.